Journal Article

Biomarkers

Sánchez-Saudinós, María Belén, Wills, Anne-Marie, Barroeta, Isabel, Selma-Gonzalez, Judit, Carmona-Iragui, Maria, Alcolea, Daniel, Morcillo-Nieto, Alejandra O, Sala, Isabel, Barragan, Eden V, Fortea, Juan, Donohue, Michael C, VandeVrede, Lawren, Illán-Gala, Ignacio, Lleó, Alberto, Dols-Icardo, Oriol, Heuer, Hilary W, Belbin, Olivia, Rubio-Guerra, Sara, Litvan, Irene, Vaqué-Alcázar, Lídia, Boxer, Adam L, Castro, Jesús Garcia, Raman, Rema, Bejanin, Alexandre, Santos-Santos, Miguel A, Rojas, Julio C

2025

Overview

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are severe neurodegenerative disorders lacking disease-modifying treatments and validated biomarkers. Clinical trials face challenges due to phenotypic overlap and imperfect clinicopathological correlations. MRI-derived models have shown to accurately predict PSP and CBD pathology in a large autopsy-confirmed cohort (Illán-Gala et al., JAMA Network Open, 2022). This study examines how participant selection based on MRI models and imaging outcomes impacts sample size estimations in hypothetical clinical trials. Eighty-four participants from the 4 Repeat Tauopathy Neuroimaging Initiative (4RTNI) with baseline and longitudinal MRI data and clinical assessments were included. Diagnoses comprised Richardson syndrome (RS, 61%) and corticobasal syndrome (CBS, 30%) without Alzheimer's disease. MRI-derived models predicted PSP, CBD, or other pathologies (MRI-PSP, MRI-CBD, MRI-Other) according to baseline MRI. Cortical thickness and volume measures were derived from MRI data using Freesurfer and employed to identify an optimal MRI-signature of regions showing the highest effect size on atrophy over 12 months using linear mixed-effects models. Disease progression was also measured with PSP Rating Scale (PSPRS). Sample sizes required to detect a 30% reduction in mean change at 12 months were calculated for hypothetical clinical trials. MRI predicted PSP, CBD, and other pathologies in 46%, 26%, and 27% of participants, respectively. Among RS diagnoses, 31 (61%) were classified as MRI-PSP; among CBS, 6 (24%) were MRI-CBD. MRI-signature regions for PSP progression included midbrain, superior-temporal, and rostral-middle-frontal thickness. For CBD, key regions included midbrain and pons volumes, superior-frontal, and entorhinal thickness. In a hypothetical PSP trial, selection criteria based on clinical diagnosis required 336 participants using PSPRS as outcome, while MRI-based diagnosis with MRI-signature as outcome reduced the sample size to 121 (64% decrease). For a CBS trial, the sample size reduced from 1301 participants if inclusion was based on clinical diagnosis to 160 using MRI-based selection and outcomes. Selecting participants with increased diagnostic certainty for PSP and CBD based on baseline MRI, combined with using MRI measures as outcomes could enhance the efficiency of future phase 2 clinical trials for 4R tauopathies. We plan to replicate these results in the Davunetide trial cohort.

• Subject: Aged / Atrophy - pathology / Biomarkers / Brain - diagnostic imaging / Brain - pathology / Corticobasal Degeneration - diagnostic imaging / Corticobasal Degeneration - pathology / Disease Progression / Female / Humans / Longitudinal Studies / Magnetic Resonance Imaging / Male / Middle Aged / Neuroimaging / Supranuclear Palsy, Progressive - diagnostic imaging / Supranuclear Palsy, Progressive - pathology